Palo Alto Investors LP Cuts Stock Holdings in Karyopharm Therapeutics Inc. $KPTI

Key Points

• Palo Alto Investors LP significantly reduced its stake in Karyopharm Therapeutics by 93.4%, now holding 324,032 shares valued at approximately $1.21 million.
• Several institutional investors have increased their holdings, with T. Rowe Price acquiring a stake worth $523,000 and Two Sigma Advisers LP growing its stake by 145.5%.
• Research analysts have mixed views on Karyopharm Therapeutics, with ratings ranging from "buy" to "sell," and a consensus rating of "Moderate Buy" along with an average target price of $34.00.

Palo Alto Investors LP trimmed its stake in shares of Karyopharm Therapeutics Inc. (NASDAQ:KPTI - Free Report) by 93.4% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 324,032 shares of the company's stock after selling 4,582,969 shares during the quarter. Palo Alto Investors LP owned approximately 3.78% of Karyopharm Therapeutics worth $1,212,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds also recently made changes to their positions in KPTI. Northern Trust Corp raised its position in shares of Karyopharm Therapeutics by 23.5% during the fourth quarter. Northern Trust Corp now owns 283,729 shares of the company's stock worth $192,000 after acquiring an additional 54,061 shares during the last quarter. Jane Street Group LLC increased its holdings in Karyopharm Therapeutics by 265.5% in the fourth quarter. Jane Street Group LLC now owns 748,306 shares of the company's stock worth $506,000 after purchasing an additional 543,556 shares in the last quarter. Focus Partners Wealth bought a new stake in Karyopharm Therapeutics in the fourth quarter worth approximately $31,000. Shay Capital LLC bought a new stake in Karyopharm Therapeutics in the fourth quarter worth approximately $116,000. Finally, Two Sigma Investments LP increased its holdings in Karyopharm Therapeutics by 60.3% in the fourth quarter. Two Sigma Investments LP now owns 137,786 shares of the company's stock worth $93,000 after purchasing an additional 51,856 shares in the last quarter. 66.44% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on KPTI shares. Wall Street Zen downgraded Karyopharm Therapeutics from a "hold" rating to a "sell" rating in a report on Wednesday, May 14th. Barclays lifted their target price on Karyopharm Therapeutics from $5.00 to $10.00 and gave the stock an "overweight" rating in a report on Tuesday, May 13th. Royal Bank Of Canada lowered their target price on Karyopharm Therapeutics from $34.00 to $33.00 and set an "outperform" rating for the company in a report on Tuesday, May 13th. HC Wainwright cut Karyopharm Therapeutics from a "buy" rating to a "neutral" rating in a research note on Wednesday, July 16th. Finally, Robert W. Baird reduced their price objective on Karyopharm Therapeutics from $42.00 to $25.00 and set an "outperform" rating for the company in a research note on Tuesday, August 12th. Four analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. Based on data from MarketBeat, Karyopharm Therapeutics currently has a consensus rating of "Moderate Buy" and an average price target of $34.00.

Karyopharm Therapeutics Stock Performance

Karyopharm Therapeutics stock traded down $0.14 during mid-day trading on Friday, reaching $6.60. The stock had a trading volume of 49,872 shares, compared to its average volume of 204,865. Karyopharm Therapeutics Inc. has a fifty-two week low of $3.51 and a fifty-two week high of $16.95. The stock's 50-day simple moving average is $5.05 and its 200-day simple moving average is $5.29. The firm has a market capitalization of $57.22 million, a PE ratio of -0.45 and a beta of 0.34.

Karyopharm Therapeutics (NASDAQ:KPTI - Get Free Report) last announced its earnings results on Monday, August 11th. The company reported ($4.32) earnings per share (EPS) for the quarter, missing the consensus estimate of ($3.80) by ($0.52). The company had revenue of $37.93 million during the quarter, compared to the consensus estimate of $37.92 million. Karyopharm Therapeutics has set its FY 2025 guidance at EPS. On average, research analysts forecast that Karyopharm Therapeutics Inc. will post -0.71 earnings per share for the current fiscal year.

Karyopharm Therapeutics Company Profile

Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).